Navigation Links
Methamphetamine Use Associated With Pulmonary Arterial Hypertension in Patients With Previously Unknown Risk Factors

- Pulmonary Hypertension Association Launches National Awareness Campaign

to Raise Awareness of Methamphetamine and PAH Link -

SILVER SPRING, Md., March 20 /PRNewswire/ -- The Pulmonary Hypertension Association (PHA), in conjunction with leading pulmonary hypertension specialists, today announced the launch of an educational campaign to raise awareness of the association between pulmonary arterial hypertension (PAH) and stimulant use, particularly methamphetamine use. While national and regional variances in methamphetamine use exist, one study conducted at the University of California, San Diego (UCSD), observed methamphetamine use in approximately 24 percent of patients with previously unknown risk factors for the disease. PAH is a rare, life-threatening blood vessel disorder of the lungs that causes the pressure in the pulmonary artery to rise above normal levels.

"We are seeing more and more PAH patients come into the clinic that are current or former methamphetamine users," said Richard Channick, M.D., professor of clinical medicine, Pulmonary and Critical Care Division at UCSD. "There is an urgency to get this message out to drug rehabilitation centers and physicians seeing patients with a history of substance abuse, and make sure they are aware of this association and of the symptoms of PAH. PAH is often misdiagnosed because the symptoms are similar to those seen with asthma and other respiratory conditions."

"Over the past few years, our physicians have made significant progress toward improving the lives of patients with PAH through earlier diagnosis, increased disease recognition, and continued development of effective therapies," said Rino Aldrighetti, president of the PHA. "However, we need to increase awareness among physicians, drug rehabilitation centers, and the general public about this association between methamphetamine usage and the development of PAH so that patients can receive proper treatment as early as possible."

In a retrospective study entitled, "Is Methamphetamine Use Associated With Idiopathic Pulmonary Arterial Hypertension," published in the December 2006 issue of CHEST, Dr. Kelly Chin and colleagues at UCSD studied rates of stimulant use -- any reported use of amphetamine, methamphetamine, or cocaine -- in 340 patients with either IPAH, PAH resulting from a known risk factor, or chronic thromboembolic pulmonary hypertension. A history of stimulant use was found in 29 percent of patients with a diagnosis of idiopathic PAH, compared with 4 percent of patients with PAH and a known risk factor, and 4 percent of patients with chronic thromboembolic pulmonary hypertension. After adjustment for differences in age and gender, patients with idiopathic PAH were eight to ten times more likely to have used stimulants than patients with these other forms of pulmonary hypertension.

About Pulmonary Arterial Hypertension (PAH)

PAH is a rare blood vessel disorder of the lung in which the pressure in the pulmonary artery rises above normal levels and may become life threatening. PAH is diagnosed when other more common causes of pulmonary hypertension such as severe emphysema, interstitial lung disease, heart failure and chronic pulmonary thromboembolism have been ruled out. Idiopathic pulmonary arterial hypertension (IPAH) refers to PAH that occurs without a known cause and is extremely rare. PAH can also occur in association with collagen vascular diseases such as scleroderma, CREST syndrome and systemic lupus erythematosus (SLE), congenital heart diseases, HIV infection and liver disease. Use of diet drugs like fenfluramine and dexfenfluramine can also lead to PAH, and an association between PAH and substance abuse, including methamphetamine, amphetamine, and cocaine use, has also been seen.

PAH is under-diagnosed because its early symptoms, including shortness of breath, chest pain, tiredness, lightheadedness, and fainting, are often misdiagnosed with those of many other conditions such as asthma. PAH has been historically chronic and incurable with a poor survival rate, because the disease has often progressed to a late stage by the time it is accurately diagnosed. However, new treatments are available which have significantly improved prognosis. Recent data indicate that the length of survival is continuing to improve, with some patients able to manage the disorder for 15 to 20 years or longer.

About the Pulmonary Hypertension Association and the Campaign

The Pulmonary Hypertension Association (PHA) is dedicated to finding ways to prevent and cure pulmonary hypertension, and to provide hope for the pulmonary hypertension community through support, education, advocacy and awareness. The vision of PHA is to improve the lives of those affected by pulmonary hypertension.

More information about PHA is available at Copies of the awareness campaign poster and other materials related to PH can be ordered by contacting

SOURCE Pulmonary Hypertension Association
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Use of Methamphetamine Among U.S. Workers and Job Applicants Drops 22 Percent in 2007 and Cocaine Use Slows Dramatically, Reports Quest Diagnostics
2. National Drug Intelligence Center Releases 2008 National Methamphetamine Threat Assessment
3. Partnership for a Drug-Free America and Council Bluffs Police Department Introduce Methamphetamine Prevention Program to Iowa Law Enforcement
4. Partnership for a Drug-Free America and Colorado Springs Police Department Introduce Methamphetamine Prevention Program to Colorado Law Enforcement
5. Methamphetamine study suggests increased risk for HIV transmission
6. ACM Partners With Tufts Associated Health Plans to Improve the Cost-effective Delivery of Home Infusion Services
7. How is H pylori adhesion to gastric cells associated with MUC1 mucin VNTR size?
8. Is increased Slug expression associated with the progression to esophageal cancer?
9. Cardiac effects associated with breast cancer treatment appear lower with dose-dense chemotherapy
10. Statement from American Water Works Association on Associated Press Story on Pharmaceuticals in Drinking Water
11. FDA Warning of Suicidal Risk Associated with Antidepressants in Juveniles and Young Adults Reviewed at Recent ISCTM Meeting
Post Your Comments:
(Date:11/29/2015)... Raleigh, NC (PRWEB) , ... November 29, 2015 , ... ... calling on their colleagues to recognize the signs of mesothelioma and push for a ... the report on its website. Click here to read it now. ...
(Date:11/28/2015)... ... November 28, 2015 , ... StatRad ... has added Chris Hafey and Claude Hooton to its board of directors. The ... North America (RSNA) 2015 Annual Meeting and continues to strategically transform its focus ...
(Date:11/28/2015)... (PRWEB) , ... November 28, 2015 , ... Pixel Film ... customizable media panels to choose from, the possibilities are endless. Users have full control ... With the ProPanel: Pulse masking effects, users are sure to get heads to turn. ...
(Date:11/27/2015)... ... ... According to an article published November 15th by ABC News, while ... light of the recent terrorist attacks in Paris, other cities are taking extra precautions ... reaching U.S. soil. Especially around special events that may be high-profile in nature, the ...
(Date:11/27/2015)... ... November 27, 2015 , ... "When I ... an inventor from Hillside, N.J. "Many people catch diseases simply from sitting on ... will always be protected from germs." , He developed the patent-pending QUDRATECS to ...
Breaking Medicine News(10 mins):
(Date:11/29/2015)... Germany , Nov. 29, 2015 /PRNewswire/ ... Imaging invites attendees to experience the most complete mobile ... highlight on display is Ziehm Vision RFD 3D, the ... a 16 cm edge length per scan volume. In ... the first fully motorized mobile C-arm in four axes ...
(Date:11/27/2015)... 2015 Une nouvelle approche ... Bremachlorin contre le cancer avancé.    ... l,immunothérapie au traitement photodynamique au Bremachlorin contre le ... Une nouvelle approche consistant à combiner l,immunothérapie au ...    Clinical Cancer Research . ...
(Date:11/27/2015)... DUBLIN , Nov. 27, 2015 Research ... of the "Global Intrauterine Devices Market 2015-2019" ... --> In this report, the author ... intrauterine devices market for 2015-2019. To calculate the market ... of following type of products: Hormonal IUDs and copper ...
Breaking Medicine Technology: